

Form Title Nicotine Replacement Therapy - Inpatient

Form Number frm-20988bond

© 2018, Alberta Health Services, CKCM



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-nd/4.0/

**Disclaimer:** This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.



## **Nicotine Replacement Therapy - Inpatient**

Last Name	
First Name	
PHN#	MRN#
Birthdate (dd-Mon-yyyy)	Physician

Select orders by replacing a ( $\checkmark$ ) in the associated box

For more information, see Clinical Knowledge Topic *Tobacco Reduction, Adult - Inpatient* http://insite.albertahealthservices.ca/klink/14163.asp

Patient Self Monitoring							
☐ Monitor for signs of nicotine toxicity, including headache, increased heart rate, dizziness, confusion, agitation, restlessness, lethargy							
☐ Notify the physician o	☐ Notify the physician of any signs of nicotine toxicity						
Medications							
Pharmacotherapy, <b>when used in combination</b> , increases chances of successful long-term cessation. Interventions for smoking cessation should be initiated during hospitalization as they may be more effective than those initiated afterward. Nicotine replacement therapy medications are also effective to provide withdrawal comfort. Smoking tobacco can alter the metabolism of a number of medications, including caffeine. This is primarily due to substances in tobacco smoke.							
Nicotine Replacement	Therapy - Initial Dose Pa	atient may administer					
Nicotine patch Choose one	☐ nicotine patch 7 mg TC  10 -19 cigarettes per day of ☐ nicotine patch 14 mg T  Greater than 19 cigarettes f ☐ nicotine patch 21 mg T  Greater than 25 cigarettes f	day (Not effective for smokeless tobacce DPICALLY daily X days r less than 3 tins per week TOPICALLY daily X days per day or 3 - 5 tins per week TOPICALLY daily X days per day or 5 tins per week (recommended mg TOPICALLY daily X days	d pharmacy consult)				
AND							
Short-acting therapy Choose one	□ nicotine gum mg PO every 1 hour PRN (recommended dose 2 mg or 4 mg) □ nicotine lozenge mg PO every 1 hour PRN (recommended dose 2 mg or 4 mg) □ nicotine inhaler 1 cartridge INHALED every 1-2 hours PRN □ nicotine mouth spray 1-2 sprays (1mg) INHALED every 30 minutes PRN						
Nicotine Replacement Therapy - Titration Patient may administer							
<ul> <li>Titration once the initial dose of NRT is optimized:         <ul> <li>Use initial dose for 6 weeks and reduce dose by 7 mg every 2 weeks thereafter.</li> <li>If strong cravings return when attempting downward titration instruct patient to remain at the higher dose for longer.</li> <li>Nicotine patch can be used for 10-12 weeks or longer if necessary.</li> <li>The short acting NRT being used in combination with the patch can be used for longer than 12 weeks as needed.</li> </ul> </li> <li>Prescriber Signature</li> <li>Date (dd-Mon-yyyy)</li> <li>Time (hh:mm)</li> </ul>							
		1					

20988Bond(Rev2018-04) Page 1 of 2



## **Nicotine Replacement Therapy - Inpatient**

Last Name		
First Name		
PHN#	MRN#	
Birthdate (dd-Mon-yyyy)	Physician	

Tobacco Cessation						
Choose either buPROPion or varenicline. They are not currently endorsed to be used together						
· · · · · · · · · · · · · · · · · · ·	PROPion and nicotine replacement therapy (NRT) can be used concurrently for the first week. NRT can not be either tapered or stopped. If strong cravings return continue NRT. Doses may need to be adjusted for al/hepatic insufficiency.					
□ buPROPion SR 150 mg PO daily X 3 days (Initial dose) Start Date (dd-Mon-yyyy)						
AND THEN	AND THEN					
□ buPROPion SR 150 mg PO BID (Maintenance dose)						
OR						
varenicline and NRT can be used concurrently for the first week. Strongly consider adding PRN NRT during the first week after starting varenicline. NRT can then be tapered or stopped. If strong cravings return continue NRT.						
□ varenicline 0.5 mg PO DAILY X 3 days <b>AND THEN</b> varenicline 0.5 mg PO BID X 4 days ( <i>Initial dose</i> ) Start Date (dd-Mon-yyyy)						
AND THEN						
□ varenicline 0.5 mg PO BID (Maintenance dose)						
Transitions and Referrals						
☐ Consult Pharmacy						
Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh:mm)				

20988Bond(Rev2018-04) Page 2 of 2